Biocryst Pharmaceuticals reported $-49640000 in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
Chemocentryx CCXI:US $ -37.22M 1.82M
Daiichi Sankyo 4568:JP Y 49252M 84953M
Enanta Pharmaceuticals ENTA:US $ -33.02M 3.4M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 2447M 673M
Glaxosmithkline GSK:US $ 2447M 673M
Intra Cellular Therapies ITCI:US $ -72.49M 13.37M
IONIS PHARMACEUT IONS:US $ -53.21M 278.25M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Mirati Therapeutics MRTX:US $ -176.51M 7.08M
Neurocrine Biosciences NBIX:US $ 58.6M 52.2M
Novavax NVAX:US $ 216.06M 1037.12M
Ptc Therapeutics PTCT:US $ -63.18M 2.97M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Sarepta Therapeutics SRPT:US $ -201.24M 125.08M
Ultragenyx Pharmaceutical RARE:US $ -137.11M 4.57M
YTE INCY:US $ 276.8M 132.69M